\
&
Contact us
This was 1 year ago
LocationBudapest, Hungary
ProgrammesThe 18th SET Plan Conference is a high-level conference organised under the patronage of the Hungarian Presidency of the Council of the EU in cooperation with the Commission.
The event will provide a platform for policymakers, researchers and industry stakeholders in energy sector to establish connections and expand collaborations aimed at developing and demonstrating innovative cleantech energy solutions, while accelerating their deployment.
This year's theme, Scaling up research, innovation and competitiveness in clean energy technologies, highlights the need to reinforce the research and innovation landscape, to enhance competitiveness and sovereignty of clean energy technology value chains within the EU.
The agenda includes several thematic parallel sessions and high-level panels in the following areas: the commercialisation of innovative technologies, industrial decarbonisations, geothermal energy, energy storage, hydrogen and skills. We are expecting high-level speakers from the Commission and the Hungarian Ministry of Energy to open the conference.
More information and agenda can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.